ArticlePloS one2013
RhoC interacts with integrin α5β1 and enhances its trafficking in migrating pancreatic carcinoma cells.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Integrin α5β1 in pancreatic ductal adenocarcinoma: Tumour‒stroma crosstalk, hypoxia and therapeutic targeting.Clinical and translational medicine · 2026Review
- Enhanced radiotheranostic targeting of integrinActa pharmaceutica Sinica. B · 2025Article
- CD73 controls Myosin II-driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells.Science advances · 2023Article
- The Cell Biology of Metastatic Invasion in Pancreatic Cancer: Updates and Mechanistic Insights.Cancers · 2023Review
- B cells in pancreatic cancer stroma.World journal of gastroenterology · 2022Review
- Role of RhoC in cancer cell migration.Cancer cell international · 2021Review
- Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma.NPJ precision oncology · 2021Article
- The Roles of Integrin α5β1 in Human Cancer.OncoTargets and therapy · 2020Review
- Evaluation of the diagnostic ability of laminin gene family for pancreatic ductal adenocarcinoma.Aging · 2019Article
- Tumor-Derived Extracellular Vesicles Require β1 Integrins to Promote Anchorage-Independent Growth.iScience · 2019Article
- Effects of silencing endothelin-1 on invasion and vascular formation in lung cancer.Oncology letters · 2017Article
- Review
- A novel anti-adhesion peptide (β3) inhibits hepatocellular carcinoma activityOncology letters · 2016Article
- Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma.The Journal of pathology · 2016Article
- The dynamics of Rho GTPase signaling and implications for targeting cancer and the tumor microenvironment.Small GTPases · 2015Review
- Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation.World journal of gastroenterology · 2014Review
- A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma.Genome medicine · 2014Article
- Spatial regulation of tumor cell protrusions by RhoC.Cell adhesion & migration · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human pancreatic ductal adenocarcinoma (PDAC) is characterized by early systemic dissemination. Although RhoC has been implicated in cancer cell migration, the relevant underlying molecular mechanisms remain unknown. RhoC has been implicated in the enhancement of cancer cell migration and invasion, with actions which are distinct from RhoA (84% homology), and are possibly attributed to the divergent C-terminus domain. Here, we confirm that RhoC significantly enhances the migratory and invasive properties of pancreatic carcinoma cells. In addition, we show that RhoC over-expression decreases cancer cell adhesion and, in turn, accelerates cellular body movement and focal adhesion turnover, especially, on fibronectin-coated surfaces. Whilst RhoC over-expression did not alter integrin expression patterns, we show that it enhanced integrin α5β1 internalization and re-cycling (trafficking), an effect that was dependent specifically on the C-terminus (180-193 amino acids) of RhoC protein. We also report that RhoC and integrin α5β1 co-localize within the peri-nuclear region of pancreatic tumor cells, and by masking the CAAX motif at the C-terminal of RhoC protein, we were able to abolish this interaction in vitro and in vivo. Co-localization of integrin α5β1 and RhoC was demonstrable in invading cancer cells in 3D-organotypic cultures, and further mimicked in vivo analyses of, spontaneous human, (two distinct sources: operated patients and rapid autopsy programme) and transgenic murine (LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre), pancreatic cancers. In both cases, co-localization of integrin α5β1 and RhoC correlated with poor differentiation status and metastatic potential. We propose that RhoC facilitates tumor cell invasion and promotes subsequent metastasis, in part, by enhancing integrin α5β1 trafficking. Thus, RhoC may serve as a biomarker and a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.